Full history for every metric is available with a Kvantra account
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 5,340 | 4,933 | 6,064 | 6,592 | 7,212 | 7,524 | 7,421 | 7,638 |
| Operating profit | €m | 1,236 | 1,237 | ||||||
| Net profit | €m | 619 | 265 | 208 | 59 | 157 | 402 | 452 | 564 |
| EPS reported | € | 0.58 | 0.67 | ||||||
| Operating cashflow per share | € | 1.52 | 1.61 | ||||||
| Capex per share | € | 0.62 | 0.48 | ||||||
| FCF per share | € | 0.91 | 1.13 | ||||||
| Free cash flow | €m | 624 | 767 | ||||||
| Net debt | €m | 7,659 | 6,943 | ||||||
| Book value equity | €m | 5,272 | 5,546 | ||||||
| Book value per share | € | 7.67 | 8.15 | ||||||
| Number of shares | m | 687.58 | 680.58 | ||||||
| DPS (TTM paid) | € | 0.23 | 0.08 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 18.45 | 14.22 | ||||||
| P/B LTM | x | 1.40 | 1.17 | ||||||
| P/S LTM | x | 0.98 | 0.88 | ||||||
| P/FCF LTM | x | 11.79 | 8.50 | ||||||
| EV/EBITDA LTM | x | 9.55 | 8.31 | ||||||
| EV/Sales LTM | x | 2.14 | 1.81 | ||||||
| Earnings Yield LTM | % | 5.42% | 7.03% | ||||||
| FCF Yield | % | 8.48% | 11.77% | ||||||
| Quality | |||||||||
| ROE | % | 7.62% | 8.43% | ||||||
| ROIC | % | 5.52% | 5.47% | ||||||
| Operating margin | % | 16.43% | 16.66% | ||||||
| Gross margin | % | 35.70% | 37.23% | ||||||
| FCF/Sales | % | 8.29% | 10.33% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +152.17% | +54.41% | ||||||
| Sales Growth YoY | % | +4.32% | -0.33% | ||||||
| Net Income Growth YoY | % | +156.11% | +51.99% | ||||||
| FCF Growth | % | -6.81% | -5.49% | ||||||
| Operating Profit Growth | % | +3.69% | -5.36% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 1.74% | 0.86% | ||||||
| Dividend Growth | % | - | -45.08% | ||||||
| Payout Ratio | % | 32.10% | 28.00% | ||||||
| FCF/Debt | x | 0.07 | 0.09 | ||||||
| Net Debt/EBITDA | x | 5.18 | 4.94 | ||||||
| EBIT/Net interest | x | 1.98 | 2.31 | ||||||
| Net debt/market cap | % | 104.10% | 106.58% | ||||||
| Net debt/Equity | x | 1.45 | 1.25 | ||||||
| Gross debt/equity | x | 1.81 | 1.54 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Grifols, S.A., a Spanish company established in 1940 and headquartered in Barcelona, specializes in the comprehensive process of acquiring, manufacturing, preparing, and distributing therapeutic products, with a primary focus on those derived from plasma. The company operates through several key divisions: Bioscience, Hospital, Diagnostic, and Bio Supplies, among others. The Bioscience division is dedicated to the research, development, production, and commercialization of plasma-derived medicines and other cutting-edge solutions. These are designed to treat individuals suffering from chronic, rare, widespread, and life-threatening medical conditions, with its product portfolio including immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division supplies a range of non-biological pharmaceutical products, clinical nutrition items, intravenous (IV) therapy solutions, and various medical devices and supplies. Grifols' Diagnostic division develops and markets advanced diagnostic tools that support healthcare professionals across the entire patient care continuum, from prevention and screening to accurate diagnosis, prognosis, and ongoing disease and treatment monitoring. Finally, the Bio Supplies division provides essential biological materials for life-science research, clinical trials, and the manufacturing of both pharmaceutical and diagnostic goods. Collectively, Grifols' offerings enable healthcare providers to effectively diagnose and treat a broad spectrum of medical conditions, such as hemophilia, various immune deficiencies, and infectious diseases. Its diverse client base includes public and private sector organizations, wholesalers, distributors, group purchasing organizations (GPOs), blood banks, hospitals, care institutions, and national health systems. Grifols also maintains a technology collaboration agreement with Mondragon.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Based on consensus from external analysts. Not Kvantra's opinion.
Grifols, S.A., a Spanish company established in 1940 and headquartered in Barcelona, specializes in the comprehensive process of acquiring, manufacturing, preparing, and distributing therapeutic products, with a primary focus on those derived from plasma. The company operates through several key divisions: Bioscience, Hospital, Diagnostic, and Bio Supplies, among others. The Bioscience division is dedicated to the research, development, production, and commercialization of plasma-derived medicines and other cutting-edge solutions. These are designed to treat individuals suffering from chronic, rare, widespread, and life-threatening medical conditions, with its product portfolio including immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division supplies a range of non-biological pharmaceutical products, clinical nutrition items, intravenous (IV) therapy solutions, and various medical devices and supplies. Grifols' Diagnostic division develops and markets advanced diagnostic tools that support healthcare professionals across the entire patient care continuum, from prevention and screening to accurate diagnosis, prognosis, and ongoing disease and treatment monitoring. Finally, the Bio Supplies division provides essential biological materials for life-science research, clinical trials, and the manufacturing of both pharmaceutical and diagnostic goods. Collectively, Grifols' offerings enable healthcare providers to effectively diagnose and treat a broad spectrum of medical conditions, such as hemophilia, various immune deficiencies, and infectious diseases. Its diverse client base includes public and private sector organizations, wholesalers, distributors, group purchasing organizations (GPOs), blood banks, hospitals, care institutions, and national health systems. Grifols also maintains a technology collaboration agreement with Mondragon.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free